708.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IDXX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$713.74
Aprire:
$710.15
Volume 24 ore:
403.49K
Relative Volume:
0.87
Capitalizzazione di mercato:
$56.68B
Reddito:
$4.17B
Utile/perdita netta:
$1.03B
Rapporto P/E:
56.16
EPS:
12.6148
Flusso di cassa netto:
$940.22M
1 W Prestazione:
+12.54%
1M Prestazione:
+12.94%
6M Prestazione:
+45.59%
1 anno Prestazione:
+63.61%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Confronta IDXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
708.45 | 56.99B | 4.17B | 1.03B | 940.22M | 12.61 |
|
TMO
Thermo Fisher Scientific Inc
|
572.41 | 212.64B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
209.95 | 148.81B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
A
Agilent Technologies Inc
|
146.74 | 41.81B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.46 | 35.91B | 15.90B | 1.28B | 2.21B | 7.2842 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Aggiornamento | Stifel | Hold → Buy |
| 2025-10-01 | Iniziato | UBS | Neutral |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-01 | Iniziato | Jefferies | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
Does IDEXX Laboratories Inc. fit your quant trading modelWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Building trade automation scripts for IDEXX Laboratories Inc.2025 Biggest Moves & Precise Buy Zone Identification - newser.com
Quantitative breakdown of IDEXX Laboratories Inc. recent moveOptions Play & Free Growth Oriented Trading Recommendations - newser.com
IDEXX Laboratories Hits Day High with 14.84% Surge in Stock Price - Markets Mojo
Will IDEXX Laboratories Inc. stock recover after recent drop2025 Macro Impact & Low Drawdown Momentum Ideas - newser.com
Why IDEXX Laboratories (IDXX) Is Up 13.6% After Strong Q3 Results and Raised 2025 Guidance - Yahoo Finance
Earnings Beat: IDEXX Laboratories, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Will earnings trigger a reversal in IDEXX Laboratories Inc.2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Agree To Buy Idexx Laboratories At $600, Earn 5.3% Annualized Using Options - Nasdaq
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) - Insider Monkey
Why retail investors favor IDEXX Laboratories Inc. stockEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Is IDEXX Laboratories Inc. stock a safe buy before earnings2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Is IDEXX Laboratories Inc. stock ready for a breakoutTrade Ideas & Daily Stock Momentum Reports - newser.com
IDEXX Laboratories Hits New 52-Week High of $734.64, Up 42.24% - Markets Mojo
IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $775.00 - MarketBeat
Blue Barn Wealth LLC Takes $225,000 Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Jacobson & Schmitt Advisors LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Bridgewater Advisors Inc. Takes Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
415 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Fullcircle Wealth LLC - MarketBeat
Bank of Montreal Can Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Arkadios Wealth Advisors Acquires New Shares in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX outlines 9.6%–10.3% revenue growth outlook for 2025 amid robust CAG Diagnostics expansion - MSN
Trend analysis for IDEXX Laboratories Inc. this week2025 Risk Factors & Reliable Breakout Forecasts - newser.com
IDEXX Laboratories Inc. (IDXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
UBS Maintains IDEXX Laboratories (IDXX) Neutral Recommendation - Nasdaq
Idexx Laboratories (IDXX) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Idexx Laboratories (IDXX) Just Overtook the 50-Day Moving Average - sharewise.com
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Cullinan Management (CGEM) and Idexx Laboratories (IDXX) - The Globe and Mail
IDEXX Laboratories (IDXX) Sees Target Price Raised by Morgan Sta - GuruFocus
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX) - Yahoo Finance
Morgan Stanley Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Raises Target Price to $805 - 富途牛牛
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $750 - 富途牛牛
UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating - MarketScreener
IDEXX Laboratories (NASDAQ:IDXX) Hits New 12-Month High Following Earnings Beat - MarketBeat
World Investment Advisors Takes $456,000 Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories (NASDAQ:IDXX) Releases FY 2025 Earnings Guidance - MarketBeat
Idexx Laboratories stock reaches 52-week high at $693.00 By Investing.com - Investing.com Australia
IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS - MarketBeat
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2025 Earnings Call Transcript - Insider Monkey
Bank of New York Mellon Corp Raises Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
A Fresh Look at IDEXX Laboratories (IDXX) Valuation After Raising Full-Year Growth Outlook - Yahoo Finance
Meta Platforms, S&P Global And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $775 to $830 - 富途牛牛
Fund Update: 16,825 IDEXX LABS (IDXX) shares added to KEYBANK NATIONAL ASSOCIATION|OH portfolio - Quiver Quantitative
Jefferies Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating - MarketScreener
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $805 From $765, Maintains Overweight Rating - MarketScreener
JPMorgan Adjusts Price Target on IDEXX Laboratories to $775 From $675, Maintains Overweight Rating - MarketScreener
BTIG Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating - MarketScreener
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $823 From $761, Maintains Outperform Rating - MarketScreener
Rothschild & Co Redburn Adjusts PT on IDEXX Laboratories to $700 From $670, Maintains Neutral Rating - MarketScreener
Why Analysts See the IDEXX Story Shifting With Upgraded Forecasts and Improved Growth Momentum - Yahoo Finance
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Idexx Laboratories Inc Azioni (IDXX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SZOSTAK M ANNE | Director |
Aug 22 '25 |
Option Exercise |
206.62 |
2,187 |
451,878 |
2,449 |
| SZOSTAK M ANNE | Director |
Aug 22 '25 |
Sale |
647.33 |
2,187 |
1,415,700 |
262 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):